ALY688: A New Peptide Showing Real Promise in Healing Heart Damage

Every year, many people suffer serious heart problems after blood flow is blocked and then restored. Doctors call this ischemia-reperfusion injury, and it still causes a lot of sickness and death even with modern treatments.

Scientists have been studying a natural hormone called adiponectin because it helps protect the heart. From that work, they created a lab-made peptide named ALY688. This new molecule is designed to act like adiponectin and wake up the same helpful pathways in heart cells.

In tests with rats that had blocked and reopened heart arteries, ALY688 was given through a vein during the blockage. It was also injected under the skin every day for four weeks. The results were impressive. Troponin-I, a protein that leaks out when heart cells are damaged, dropped to lower levels. Fewer heart cells died. The size of the damaged area shrank. And the heart kept pumping better than expected.

Digging deeper, the team saw that ALY688 helped clean up damaged cell parts through a process called autophagy. It also lowered harmful molecules called reactive oxygen species and stopped cells from triggering their own self-destruct programs. This happened both in living rats and in heart cells grown in the lab that were starved of oxygen and then reoxygenated.

Using proteomics, which is a way to study thousands of proteins at once, the researchers noticed something interesting. A protein named Rab8a usually drops during heart injury, but ALY688 kept its levels steady. ALY688 also boosted the number of tiny bubbles called extracellular vesicles, both in the heart and in the blood. These vesicles from treated animals carried special protein packages linked to energy use and stress defense. When scientists put these vesicles onto damaged heart cells in dishes, those cells were protected too.

To prove Rab8a really mattered, the team used CRISPR gene editing to remove it. Without Rab8a, ALY688 could not make as many protective vesicles, and the shielding effect weakened. This shows ALY688 works in two ways. It directly shields heart cells, and it also triggers Rab8a to build vesicles that spread the protection even further. Together, these findings point to ALY688 as a strong candidate for treating ischemia-reperfusion injury in the future.